1348P Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: results from two phase II studies.
Authors
Lidbrink, EErfan, J
Chmielowska, E
Otremba, B
Bouhlel, A
Lauer, S
Hermoso, M
Nuesch, E
Shing, M
Misra, Vivek
Affiliation
Thoracic Surgery, Kindai University School of Medicine, 577-8502 - Osaka/JPIssue Date
2017